These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30061240)

  • 21. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
    Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X
    Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
    Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy.
    Halldorsson MO; Hauptmann M; Snaebjornsson P; Haraldsdóttir KH; Aspelund T; Gudmundsson EF; Gudnason V; Jonasson JG; Haraldsdottir S
    Scand J Gastroenterol; 2018 Aug; 53(8):972-975. PubMed ID: 30010450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LDH-A negatively regulates dMMR in colorectal cancer.
    Zhang Y; Li J; Wang B; Chen T; Chen Y; Ma W
    Cancer Sci; 2021 Aug; 112(8):3050-3063. PubMed ID: 34110068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
    Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.
    Haraldsdottir S; Roth R; Pearlman R; Hampel H; Arnold CA; Frankel WL
    Fam Cancer; 2016 Apr; 15(2):253-60. PubMed ID: 26666765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.
    van der Heide DM; Turaga KK; Chan CHF; Sherman SK
    J Surg Res; 2021 Oct; 266():104-112. PubMed ID: 33989889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of novel models for predicting mismatch repair protein deficiency and relevant disease-free survival in colorectal cancer patients.
    Xu Y; Li Y; Zhu Z; Yang J; Tan Y; Wang Y; Xu X
    Int J Colorectal Dis; 2022 Jun; 37(6):1449-1464. PubMed ID: 35482069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for an Association of ERCC1 Expression and Mismatch Repair Status with Overall Survival in Colorectal Cancer Patients.
    Li P; Xiao ZT; Braciak TA; Ou QJ; Chen G; Oduncu FS
    Oncol Res Treat; 2017; 40(11):702-706. PubMed ID: 29065415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers.
    Li J; Guo Y; Liu J; Guo F; Du L; Yang Y; Li X; Ma Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.
    Etienne-Grimaldi MC; Mahamat A; Chazal M; Laurent-Puig P; Olschwang S; Gaub MP; Formento JL; Formento P; Sudaka A; Boige V; Abderrahim-Ferkoune A; Benchimol D; André T; Houry S; Faucheron JL; Letoublon C; Gilly FN; Delpero JR; Lasser P; Pradere B; Pezet D; Penault-Llorca F; Milano G
    Br J Cancer; 2014 May; 110(11):2728-37. PubMed ID: 24800948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study.
    Wang Z; Tang X; Wu X; Yang M; Wang D
    Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31804673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors.
    Takehara Y; Nagasaka T; Nyuya A; Haruma T; Haraga J; Mori Y; Nakamura K; Fujiwara T; Boland CR; Goel A
    J Transl Med; 2018 Jan; 16(1):5. PubMed ID: 29329588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sporadic deficient mismatch repair in colorectal cancer increases the risk for non-colorectal malignancy: A European multicenter cohort study.
    Gkekas I; Jan N; Kaprio T; Beilmann-Lehtonen I; Fabian P; Tavelin B; Böckelman C; Edin S; Strigård K; Svoboda T; Hagström J; Barsova L; Jirasek T; Haglund C; Palmqvist R; Gunnarsson U
    J Surg Oncol; 2024 Jun; 129(7):1295-1304. PubMed ID: 38470492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
    Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
    Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic immunohistochemical screening for mismatch repair and ERCC1 gene expression from colorectal cancers in China: Clinicopathological characteristics and effects on survival.
    Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
    PLoS One; 2017; 12(8):e0181615. PubMed ID: 28767665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colon cancer CT staging according to mismatch repair status: Comparison and suggestion of imaging features for high-risk colon cancer.
    Hong EK; Chalabi M; Landolfi F; Castagnoli F; Park SJ; Sikorska K; Aalbers A; van den Berg J; van Leerdam M; Lee JM; Beets-Tan R
    Eur J Cancer; 2022 Oct; 174():165-175. PubMed ID: 36029713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.